Skip to the page

Data / Drug companies / Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation: 190 products in the FDA NDC directory, labeler code 0078

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Novartis Pharmaceuticals Corporation (labeler code 0078) lists 190 products in the FDA National Drug Code Directory, covering 55 finished drugs by generic name. By type: 163 prescription drugs, 25 bulk ingredients. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 30, 2025.

The request: Watch Novartis Pharmaceuticals Corporation (FDA labeler code 0078): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0078
Products in commercial distribution
190
Packages
223
Finished drugs by generic name
55
Prescription products
163
Over the counter products
0
Controlled substance products
Schedule II 8
Flagged as original packager
118 of 118 products that carry the flag
Started marketing in the last 12 months
0
Products with a marketing end date set
13
Earliest marketing start
March 11, 1968
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)14375.3%
Bulk ingredients2513.2%
Biologics (BLA)126.3%
Drugs for further processing105.3%

Products by type

TypeProductsShare
Prescription drugs16385.8%
Bulk ingredients2513.2%
Cellular therapies21.1%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Everolimus1115
Deferasirox921
Dexmethylphenidate hydrochloride817
Alpelisib71
Sacubitril and valsartan729
Valsartan738
Cyclosporine624
Octreotide acetate611
Eltrombopag olamine67
Valsartan and hydrochlorothiazide521
Amlodipine valsartan and hydrochlorothiazide51
Carbamazepine552
Oxcarbazepine446
Secukinumab41
Amlodipine besylate and valsartan41
Imatinib mesylate317
Trametinib31
Rivastigmine311
Siponimod31
Asciminib31
Dabrafenib31
Ribociclib31
Nilotinib310
Mycophenolic acid216
Basiliximab21
Tisagenlecleucel21
Fingolimod hcl22
Capmatinib21
Canakinumab11
Tobramycin and dexamethasone114
Neomycin sulfate, polymyxin b sulfate and dexamethasone111
Lifitegrast13
Remibrutinib11
Topotecan hydrochloride14
Betaxolol hydrochloride13
Nepafenac12
Atrasentan11
Iptacopan11
Lutetium lu 177 vipivotide tetraxetan11
Letrozole117
Deferoxamine mesylate16
Rydapt11
Lapatinib14
Triclabendazole11
Ofatumumab11
Kit for the preparation of gallium ga 68 gozetotide11
Tobramycin141
Brolucizumab11
Triamcinolone acetonide177
Clofazimine11
Artemether and lumefantrine11
Ceritinib11
Crizanlizumab11
Inclisiran11
Pazopanib hydrochloride13

Dosage forms

Dosage formProductsShare
Tablet, film coated5428.4%
Tablet2714.2%
Powder136.8%
Liquid126.3%
Injection, solution94.7%
Capsule, extended release84.2%
Capsule84.2%
Tablet, for suspension73.7%
Capsule, liquid filled63.2%
Kit52.6%
Injection52.6%
Granule42.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Rhapsido0078-1483TabletNew drug applications (NDA)September 30, 2025
Vanrafia0078-1420Tablet, film coatedNew drug applications (NDA)April 2, 2025
Triesence0078-0897Injection, suspensionNew drug applications (NDA)October 1, 2024
Vijoice0078-1175GranuleNew drug applications (NDA)April 24, 2024
Entresto0078-1238PelletNew drug applications (NDA)April 12, 2024
Entresto0078-1231PelletNew drug applications (NDA)April 12, 2024
Tislelizumab0078-1511LiquidBulk ingredientsMarch 14, 2024
Iptacopan0078-1455PowderBulk ingredientsDecember 5, 2023
Fabhalta0078-1189CapsuleNew drug applications (NDA)December 5, 2023
Cosentyx0078-1168Injection, solution, concentrateBiologics (BLA)October 6, 2023
Adalimumab-adaz0078-1329LiquidBulk ingredientsJuly 1, 2023
Mekinist0078-1161Powder, for solutionNew drug applications (NDA)March 16, 2023
Tafinlar0078-1154Tablet, for suspensionNew drug applications (NDA)March 16, 2023
Alpelisib0078-1364PowderBulk ingredientsApril 5, 2022
Vijoice0078-1035KitNew drug applications (NDA)April 5, 2022
Vijoice0078-1028TabletNew drug applications (NDA)April 5, 2022
Vijoice0078-1021TabletNew drug applications (NDA)April 5, 2022
Locametz0078-1224Injection, powder, lyophilized, for solutionNew drug applications (NDA)March 23, 2022
Pluvicto0078-1217Injection, solutionNew drug applications (NDA)March 23, 2022
Leqvio0078-1000Injection, solutionNew drug applications (NDA)December 22, 2021
Scemblix0078-1196Tablet, film coatedNew drug applications (NDA)October 29, 2021
Scemblix0078-1098Tablet, film coatedNew drug applications (NDA)October 29, 2021
Scemblix0078-1091Tablet, film coatedNew drug applications (NDA)October 29, 2021
Ferumoxytol0078-1357LiquidBulk ingredientsJuly 15, 2021
Ofatumumab0078-1539LiquidBulk ingredientsAugust 20, 2020

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.